Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

100.80DKK
18 May 2018
Change (% chg)

kr.-0.20 (-0.20%)
Prev Close
kr.101.00
Open
kr.100.80
Day's High
kr.102.20
Day's Low
kr.100.20
Volume
61,375
Avg. Vol
94,327
52-wk High
kr.141.00
52-wk Low
kr.78.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 0.96
Market Cap(Mil.): kr.3,109.28
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -9.58 -- --
ROI: -42.93 -8.07 12.63
ROE: -67.51 -10.87 14.50

BRIEF-Zealand Pharma Announces Interim Report For The First Quarter Of 2018

* ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018 Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018

Apr 27 2018

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

Apr 26 2018

BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon

April 11 Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu :

Apr 11 2018

BRIEF-Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care

* HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE

Apr 11 2018

BRIEF-Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia

* REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE

Mar 20 2018

BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​

* FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO

Mar 07 2018

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 20 2018

BRIEF-Zealand Reports Royalty Revenue Of DKK 11.3 Mln For Q4 2017

* REG-ZEALAND REPORTS ROYALTY REVENUE FOR THE FOURTH QUARTER OF 2017

Feb 07 2018

Biotech Zealand Pharma bets on self-marketing over big pharma partnerships

GLOSTRUP, Denmark, Jan 30 Denmark's Zealand Pharma is pinning its strategy on rare disease drugs that the small biotech can market itself after seeing disappointing income from a diabetes drug marketed by partner Sanofi, its chief executive said.

Jan 30 2018

Earnings vs. Estimates